Sulfabid is developed by Purdue Frederick.

What development phase is Sulfabid in?

Sulfabid is FDA-approved (marketed).

What is the generic name of Sulfabid?

SULFAPHENAZOLE is the generic (nonproprietary) name of Sulfabid.

Last reviewed 2026-05-13 · How we verify

Sulfabid (SULFAPHENAZOLE)

Purdue Frederick · FDA-approved approved Small molecule Quality 14/100

Sulfabid (Sulfaphenazole) is a small molecule drug developed by Purdue Frederick, targeting the Cytochrome P450 2C9 enzyme. It is classified as a sulfaphenazole and was FDA approved in 1974. Sulfabid is off-patent and has no active Orange Book patents, indicating it is available as a generic. However, there are currently no generic manufacturers listed. As an off-patent drug, its commercial status and availability may be subject to change.

At a glance

Generic name	SULFAPHENAZOLE
Sponsor	Purdue Frederick
Drug class	sulfaphenazole
Target	Cytochrome P450 2C9, Dihydropteroate synthase
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved
First approval	1974

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sulfabid CI brief — competitive landscape report
Sulfabid updates RSS · CI watch RSS
Purdue Frederick portfolio CI